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Abstract Evidence-based guidelines are important tools
and common pathways for translating evidence into clinical
practice. It is most urgently needed when significant hetero-
geneity in practice exist. Actively engaging opinion leaders
in the process of evidence-based guidelines development is
important for several reasons. These include allowing the
collective views of the practice communities to be repre-
sented, resolving heterogeneity in practice through discus-
sion, and allowing credible recommendations to be
formulated. Most importantly, the process itself is a tool
for facilitating dissemination and implementation. Recogniz-
ing the gap between practice pattern and guideline recommen-
dations, and devising strategies to address it represent an
important step toward maximizing concordance between
guideline and practice. Evidence-based recommendations
serve as important reference points, against which we can
measure, debate, and innovate from.
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Introduction
The management of curable rectal cancer has undergone
significant change in recent years. Advances have been
made in each of the disciplines involved in the care of
patients with rectal cancer, with notable and significant
improvements in surgery, radiotherapy, chemotherapy, radi-
ology, and pathology. The strong interrelationship between
these modalities means successful implementation of one
strategy (or not) directly affects the readiness and appropri-
ateness for change in another. For these reasons, strong,
coordinated, and efficient process(es) are needed to optimize
the uptake of evidence into practice, translating knowledge
into improvement in patient outcomes.
Evidence-based guidelines are important tools, as well as
a strategy for translating evidence into clinical practice. The
reason why they are embraced by the medical community, is
the methodological rigor available supporting the creation of
evidence-based guidelines. Methods for evidence synthesis
and appraisal have been well described and practiced [1].
Processes suitable for creating evidence-based guidelines
for different medical communities have been established
[2–5]. Tools to evaluate guideline quality such as the
AGREE II instrument [6] are gaining international recognition
and adoption. Databases to facilitate access and comparison
between guidelines are comprehensive and accessible [7, 8].
Strategies for adapting guidelines from one jurisdiction to
another, in an effort to share productivity and broaden gener-
alizability, have also been described [9].
Despite these methodological advances, the final step
between guidelines and adoption into clinical practice, i.e.,
implementation, remains an inexact science. While it would
be ideal to have a template for efficient change implemen-
tation, a single set of strategy that would apply to all clinical
domains or circumstances does not exist. Rather, general
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principles, which can be modified based on the clinical
scenario, political environment, and organizational struc-
ture, are likely to provide the blueprint in moving forward.
What do we know about the best way of producing
consensus and buy-in to evidence-based guidelines? In this
paper, we will discuss what is known generally in this topic.
Using the changing role of radiotherapy in the management
of localized rectal cancer, we will describe how these prin-
ciples are applied to motivate change and guideline imple-
mentation in a clinical practice environment.
Strategies toward Guideline Consensus and Guideline
Adoption: What Does the Literature Tell Us?
Multiple acceptable options, with weak evidence to guide
selection between them translate into heterogeneity practice
environments. The availability of multiple standards of
practice makes it difficult to evaluate the quality of care,
confusion for patients, and dilute the opportunity to refine
excellence in selected strategies. Having clinical practice
guidelines become most pressing when heterogeneity in
treatment approach occurs within the practice environment.
The value of evidence-based guidelines lies far beyond
the resulting recommendations alone. Rather, the process of
guidelines development is itself a strategy by which buy-in
and acceptance is nurtured and created. Guidelines develop-
ment processes share a similar core structure. First, the
process begins with the provision of a forum in which
evidence is systematically brought together, appraised, and
debated in order to reach consensus. This consensus is
further reinforced and contextualized by external consulta-
tive and review processes. Second, the network of opinion
leaders brought together for the task of building consensus
and creating recommendations are often the same opinion
leaders charged with dissemination and implementation at a
local level. Similarly, these opinion leaders are often recruited
into other networks, with the mandate and ability to initiate
policy changes. It is this active engagement of “networks of
opinion leaders” that is the cornerstone for dissemination and
implementation inherent in many evidence-based guidelines
development processes.
What does the literature tell us about the science of how
to establish consensus among experts, and implementation
strategies beyond the guideline development process itself?
These questions are the subject of much research although
the fields are still evolving.
Consensus Methods
Even when high-quality evidence is available, our individ-
ual knowledge, interpretation of the evidence, and opinions
are influenced by many factors including past experiences,
peer opinions, time to learn, and critical appraisal skills to
name just a few. These factors influence our recommenda-
tions and opinions even more when the available evidence is
sparse. New evidence may encounter no barriers in “uptake”
given its confirmatory nature to local practice, but in other
contexts, be critiqued against a high threshold for accep-
tance when its conclusions go against standard practice.
Consensus methods are called upon to narrow heterogeneity
and allow the best collective opinion to be made.
Within the taxonomy used within consensus methods re-
search, the most common method of establishing consensus in
clinical practice is generally referred to as an “informal” pro-
cess. Groups are brought together (e.g., tumor board), are free
to interact with the aim of reaching an agreement. This could
work well in many circumstances. Behavioral science research
would highlight some disadvantages with this approach, how-
ever. Individuals often behave differently in the presence of
peers. Somemay feel pressured to alter their opinion especially
if theirs are different from those of the group. Formal methods
on the other hand are created with the basic assumption that by
explicitly involving all members of a group, it is more likely
that all the appropriate arguments will be considered and
therefore more likely to lead to the “right” decision [10••]. It
is generally more labor intensive. Three formal methods most
frequently used in health care research and modified for guide-
lines consensus development are described below.
The Delphi method involves the use of questionnaires
where respondents are asked to express their recommenda-
tions or choices they feel the group should consider. The
results are aggregated and returned to the respondent so that
his/her response is juxtaposed against the response emerging
from the group. From here, the individual is invited to modify
his/her response. This approach minimizes the potential of
dominant characters on the final decision, employs statistics
to incorporate participants’ views, but places less emphasis on
direct information exchange between participants.
The nominal group technique starts with each participant
recording their ideas independently and privately. The ideas
are then listed in a round-robin format until no new ones are
expressed. The ideas are then discussed in turn. Finally, a
voting process takes place and the individual judgments are
synthesized statistically to arrive at the group’s final judgment.
The consensus development conference method involves
bringing a select group of individuals together with the
objective of arriving at consensus about an issue. Evidence
is presented in an open forum, and the panel deliberate
before arriving at a decision.
Most clinical guidelines development groups have employed
informal, or versions of the consensus development conference
methods. This is because of the strong parallel between achiev-
ing consensus in clinical guidelines and clinical decision-
making. The validity of the recommendations hinge heavily
on the breathe of the consultative process, composition of the
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panel, in addition to the rigor of the evidence. The best method
to use would depend on the questions that need to be addressed
[11, 12].
Guideline Dissemination and Implementation Strategies
Explicit guideline dissemination and implementation strate-
gies should ideally be planned, for each recommendation
that calls for a change in practice. Which method(s) to use
depend on a number of factors including the clinical context,
who and what we are trying to change, as well as resource
availability. The Cochrane Effective Practice and Organiza-
tion of Care (EPOC) group described a set of taxonomy to
facilitate reporting and communication in this domain. Com-
mon strategies that have been studied include educational
materials, educational meetings, local consensus processes,
educational outreach visits, local opinion leaders, patient-
mediated interventions, audit and feedback, reminders, mar-
keting approaches, and mass media.
Several systematic reviews addressing the question
“which of the dissemination and implementation strategies
are most effective” have been published and they share
similar conclusions [13••, 14, 15••]. Clear enunciation of
the known barriers and facilitators the strategies are
intended to address should be considered. While there are
some suggestions that multifaceted strategies have a stron-
ger effect, perhaps owing to the fact that they are more likely
to address multiple barriers, it may not yield proportionally
more benefit. Costs and benefits of different strategies need
to be considered especially when limited resources are
available. It may be more efficient to use a cheaper, more
feasible, but less effective intervention, than a more expen-
sive but potentially more effective method.
Measuring Adherence
The final step to confirm buy in and impact of guidelines is
to examine the level of concordance between practice and
guideline recommendations. Selecting the parameter(s) for
measuring compliance is not always straight forward. The
National Quality Measures Clearinghouse recommended
that the parameters selected should have three core charac-
teristics. It should be supported by evidence, have sound
measurement properties, and be available and accessible
within the timeframe(s) of interest [16].
Once the metrics are selected, making an explicit judgment
on what level of guideline concordance is optimal, and what
key confounding factors are required for interpreting the com-
pliance level, requires careful consideration [17]. For exam-
ple, patient preferences may result in a treatment decision
different from what was recommended. Comorbid conditions
may result in reversal of the risk-benefit ratio [18]. Frailty (a
term encompassing declining functional reserve, conferring
vulnerability to disability, hospitalization, nursing facility ad-
mission, and death) beyond the impact of age and known
medical conditions deserves consideration [19–21]. For new
procedures to be practiced, adequacy of training, provision of
resources, and accessibility need to be considered. Adminis-
trative data sources used to generate guideline concordance
data may underestimate compliance and audits to estimate the
level of discrepancy will facilitate interpretation [22].
Degree of adherence to guidelines, be it strong or
weak, is seldom solely attributable to the strength or
quality of the guidelines themselves. There are many
systems that may influence or impede behavior aligning
with the recommendations. These include the character-
istics of the primary studies, training of the clinical team,
and appropriate human and financial resources to name a
few. Understanding the specific contribution of the guideline
per se is often challenging. While concordance indicators can
represent a convenient way to set bench marks, providing
sufficient information to help users interpret and understand
the data correctly is required.
The Clinical Context: Rectal Cancer and the Role
of Radiotherapy
The same body of evidence should be available to answer the
same question conducted by any reviewer. However, the way
it is interpreted and applied can vary both at the individual and
community level. How radiotherapy is used in the manage-
ment of rectal cancer is a good example. Its application has
evolved quite differently in Europe versus North America
[23•]. An understanding of the differences in practice environ-
ments is essential to consider the promoters and barriers
toward concordance with standards and recommendations.
In North America, the NIH consensus guideline was
powerful in establishing the long course (5 weeks) postop-
erative pelvic radiotherapy as the standard of practice in the
1990s [24]. Since then there has been a gradual shift toward
adoption of preoperative long course chemoradiotherapy so
that it became the dominant practice pattern since the 2000s.
While this was motivated by the conclusions from the
Swedish [25] and Kapeteijn’s [26] studies published in
1997 and 2001, respectively, this adoption of preoperative
radiotherapy in North America was only in part consistent
with the key evidence available at the time [25, 26]. Despite
the fact that both studies employed the short-course (5 days)
regimen, the use of the long course (5 weeks), a translation
of the postoperative regimen into the preoperative setting
which adheres to the use of standard dose per fraction (2 Gy)
was generally used. The reasons are likely multifactorial.
North American radiation oncologists subscribe to the ra-
diobiological principles that standard dose per fraction is
less likely to cause late toxicities and in the absence of
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evidence at the time, “believed” that the standard dose per
fraction is at least equivalent (if not potentially superior) to
the SCRT that was used within the primary studies. The
transition of delivering a 5-week course of radiotherapy
postoperatively to preoperatively has little resource implica-
tions and was readily implementable. There were also other
forces at play. For example, preoperative radiotherapy was
embraced by our surgical colleagues in part owing to the
positive clinical observations of improved resectability and
“minimal” incremental perioperative complications, facili-
tating rapid adoption. The use of SCRT on the other hand,
requires rapid coordination between radiotherapy and sur-
gery which present practical challenges.
The evolution in clinical practice in Europe was quite
different. In Sweden, where short-course preop RT was first
demonstrated to confer a survival benefit, SCRT was the
dominant practice in 2001 [27] reflective of effective uptake
of the results from the Swedish rectal trial [25], as was the
practice in the UK [28•]. The publication of the UK MRC-
led study CR07 NCIC CTG CO16 [29] in 2009 reinforced
the superiority of short-course radiotherapy (SCRT) over
selective postoperative radiotherapy [30].
The evidence as described in the EORTC study in sup-
port of the use of long-course CRT preoperatively came
after in 2004 [31]. In North American, this evidence is easily
adopted since it is consistent with the standard practice of
using long-course CRT. Its interpretation within European
practice required more active debate.
The primary evidence by Bujko et al. suggesting no
difference between short-course and long-course chemora-
diotherapy [32] was at once interpreted as consistent with
ongoing practice of SCRT in Europe, and consistent with
long-course radiotherapy in North America.
From Consensus Development to Implementation:
Ontario Rectal Cancer Guideline
The Ontario rectal cancer evidence-based guidelines were
created under the auspices of the Cancer Care Ontario
Program in Evidence-Based Care. The heterogeneity factor,
with multiple acceptable approaches, has motivated each
update to our guideline (Table 1). The first rectal cancer
guideline published in 2000 [33] addressed whether preop-
erative radiotherapy should be used in patients with resect-
able rectal cancer. The recommendations supported the use of
postoperative radiotherapy and/or chemotherapy for resected
stage II or III disease, emphasizing the benefit of being able to
add radiotherapy selectively only to patients who need it when
the decision is made based on pathological stage. The second
rectal cancer guideline published in 2003 [34] recommended
preoperative radiotherapy as an acceptable alternative to post-
operative treatments. The third guideline published in 2010
recommended the use of preoperative chemoradiotherapy
(long course). Preoperative radiotherapy alone with long
course, short course, or postoperative chemoradiotherapy were
all considered acceptable standards in addition. Rationale guid-
ing the choice between these options were deliberated [35•].
Consensus Development, Dissemination, and Implementation
Inherent within the guidelines development process, achiev-
ing consensus hinges first on the active engagement of a
“network of opinion leaders.” Within the Program in
Evidence-Based Care for Cancer Care Ontario, this began
with the composition of the guidelines expert panel itself.
Each expert panel consists of opinion leaders, representing
the relevant disciplines, the geographic diversity across the
province, and methodologists. The topic formulation and
prioritization is driven by the group itself to represent the
needs of the community it represents. The guideline devel-
opment cycle [2] includes rigorous methodologies for ques-
tion definition, evidence synthesis, and crafting of the
recommendations. The recommendations are presented to
the users accompanied by a summary of the key evidence
and qualifying statements. These statements, while succinct,
are crafted carefully, and reflect several iterations, modifi-
cations, and consensus achieved through discussion.
An example behind the most recent version of the rectal
guideline perhaps serves to illustrate the effect of these
consensus discussions. The final guideline recommended
the use of radiotherapy for all patients with SII and III
disease. Significant discussion occurred during the recom-
mendation formulation as to whether there are subgroups of
patients where the benefits of preoperative radiotherapy
outweigh its toxicities such as in higher rectal lesions,
node-negative disease, and in expert hands where high-
quality TME procedures are anticipated. While the panel
acknowledged that under these specific circumstances, the
toxicity may outweigh the benefits, the appropriateness of
articulating this within the guidelines were felt to be prema-
ture within our practice environment. The ability to incor-
porate these refinements within the guideline requires
uniformity in reporting standards for staging MR and
pathology, which was still in development across the prov-
ince. The panel members acknowledged the variation in
opinions but arrived at a consensus to recommend preoper-
ative radiotherapy including these subgroups, recognizing
that refinements could occur in time. A second consensus
debate occurred around the use of SCPRT. This was not
commonly considered across Ontario. The implementation
of SCRT, while supported by evidence, represents a change
from our standard practice. The rationale for change and cir-
cumstances when this should be used, relative to the standard
approach was needed. The final recommendation wording of
“hypofractionated (short course 25 Gy in five fractions)
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radiotherapy is an acceptable alternative to standard long
course chemoradiotherapy” represents the panels’ adaptation
of the evidence into our practice environment.
Prior to formal adoption and dissemination, the draft docu-
ments go through a series of reviews including an internal and
external review with the ultimate goal of maximizing its
quality and credibility. The internal review panel (2–3
reviewers) is charged with the task of ensuring each PEBC
document is developed in a methodologically rigorous fashion
and that the recommendations were supported by the evidence
in a transparent way. The external review process included
soliciting opinion from oncologists within Ontario and tar-
geted external peer reviewers [36]. Review comments and
changes to the original recommendations were synthesized
and incorporated in the guidelines document itself.
Finally, dissemination was accomplished by posting of
the guidelines onto the central website [37], registration in
the Guidelines clearinghouse [8], evaluation and posting
with the Inventory of Cancer Guidelines with the Canadian
Partnership Against Cancer (http://www.cancerguidelines.
ca; http://www.cancerview.ca/portal/server.pt/community/
sage/521/sage), and publication of the systematic review
and recommendations in peer-reviewed journal [35•].
The multiple-step process meant that our complete guide-
line development cycle typically takes approximately
18 months to complete. In clinical areas where there are
active changes in clinical practice processes (e.g., availability
of high-quality MRI for staging in clinical environment where
this was not readily accessible previously) or where high-
impact clinical trial results are released, matching response
to a rapidly changing environment could be challenging.
Mechanism is in place to ensure available guidelines were last
updated within 5 years, however.
While designing an explicit implementation plan was be-
yond the scope of the Program in Evidence-Based Care, the
active engagement of the network of opinion leaders continues
to exert its influence in promoting clinical uptake and adoption
beyond the dissemination stage. At a physician level, Ontario
oncologists uniformly participate in regular multidisciplinary
tumor boards serving as a forum for real-time peer review. The
opinion leaders serve as advocates for the provincial recom-
mendations in these settings. The guideline recommendations
became current topics and agenda items at regional conferences
allowing further deliberation and alignment of practices to
occur. The opinion leader network charged with creating these
recommendations overlaps, and works synergistically with
Table 1 Summary of key questions and recommendations for radiotherapy and rectal cancer from the Cancer Care Ontario Program in Evidence-
Based Medicine
Question 2000 [33] Should we use preoperative radiotherapy in patients with resectable rectal cancer to improve local recurrence
and survival?
Recommendation Randomized trials demonstrate that radiotherapy before surgery is significantly more effective than surgery
alone in reducing local recurrence and probably death in patients with resectable rectal cancer.
However, preoperative radiotherapy requires treatment of most rectal cancer patients regardless of the stage of
the disease and consequent exposure to the risk of radiation-induced morbidity and mortality. Furthermore,
when considering all rectal cancer patients, stage-selective postoperative radiotherapy is as effective as less
stage-selective preoperative radiotherapy and should remain the standard treatment.
Patients with evidence of advanced clinical stage but resectable rectal cancer should be encouraged to participate
in clinical studies testing the role of preoperative radiotherapy alone or combined with chemotherapy.
Question 2003 [34] Should patients with resectable rectal cancer receive preoperative radiotherapy to improve survival and local
recurrence?
Recommendation • Preoperative radiotherapy is an acceptable alternative to the previous practice of postoperative radiotherapy
for patients with stage II and III resectable rectal cancer.
• Both preoperative and postoperative radiotherapy decrease local recurrence but neither improves survival as
much as postoperative radiotherapy combined with chemotherapy. Therefore, if preoperative radiotherapy is
used, chemotherapy should be added postoperatively, at least to patients with stage III disease.
Question 2010 [35•] Following appropriate preoperative staging tests, should patients with resectable stage II/III rectal cancer be
offered preoperative radiotherapy (with or without chemotherapy)?
Recommendation • Preoperative chemoradiotherapy is preferred, compared with preoperative radiotherapy (standard fractionation:
longer course 45–50.4 Gy in 25–28 fractions) alone, to decrease local recurrence.
• Preoperative chemoradiotherapy is preferred, compared with a postoperative approach, to decrease local
recurrence and adverse effects.
• For patients with relative contraindications to chemotherapy in the preoperative period, acceptable alternatives
are preoperative standard
fractionation (longer course 45–50.4 Gy in 25–28 fractions) or hypofractionation (short course 25 Gy in five
fractions) radiotherapy alone followed by surgery, guided by the risk of adverse effects.
• Patients eligible for preoperative radiotherapy with or without chemotherapy should also be considered for
adjuvant chemotherapy.
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networks charged with creating recommendations in other re-
lated topics such as imaging [38], surgery and pathology [39],
and multidisciplinary case conferences [40]. At a policy maker
level, Cancer Care Ontario, the formal cancer program for the
province of Ontario (of which the Program in Evidence-Based
Care is a part of), has a breadth of levers to facilitate the
application of evidence into practice and policy formation.
For example, the Cancer System Quality office, charged with
the mandate of reporting on the state of the Ontario cancer
system, incorporates guideline adherence parameters as part of
our “report card” on cancer care. Educational medical work-
shops and performance management strategies form part of the
response to published quality metrics. High-quality evidence-
based guidelines developed within the PEBC set off a ripple
effect that is central to facilitating buy in, implementation, and
steps for future improvements.
How Concordant Are We?
The percentage of patients with SII and III rectal cancer
receiving CRT were felt to be the most useful quality meas-
ures for the guidelines relevant to our rectal guidelines [24].
This is supported by several systematic reviews [41, 42].
The availability of this parameter was limited by the report-
ing of stage, and details of radiotherapy prescription at a
provincial level, and requires some degree of inference. The
Cancer Quality Council of Ontario (CQCO) reported on the
practice pattern for rectal cancer in 2002, suggesting the
proportion of patients treated with preoperative radiotherapy
was approximately 15%. The Canadian Partnership Against
Cancer provided a quality report using 2007 data report-
ing the proportion of patients receiving any radiotherapy
was 52% in Ontario while the proportion receiving this
preoperatively was 50%. In 2009 Ontario data would
suggest while the proportion of patients receiving any
radiotherapy remains stable at approximately 50%, the
proportion receiving this preoperatively has risen to
62% (Unpublished data). These practice patterns align with
the recommendations in 2000 for postoperative CRT, 2003 for
preoperative RT as an acceptable alternative, and 2010 for
preoperative CRT as the standard of practice.
These findings cannot support a cause and effect be-
tween our guidelines and practice pattern. What is clear,
however, is that the rigorous process of developing high-
quality evidence-based guidelines created by a network
of opinion leaders allows differences in opinion between
opinion leaders to be explicitly discussed, consensus reached
(or at least differences articulated), and what is needed to
further advance patient outcomes described. The convergence
of opinions through this process meant the availability
of transparent sets of recommendations and benchmarks
(and the rationale behind them) for the communities, its
practitioners, and patients. Evidence-based guideline
recommendations serve as important references against which
we measure, debate, and innovate from.
Conclusions
Evidence guiding the best consensus building, guidelines
dissemination, and implementation strategies is incomplete
but growing. A network of opinion leaders built for creating
evidence-based guidelines, actively engaged by an effective
consensus development process, represents one of the most
effective ways toward achieving excellence in quality of
care. Evidence-based recommendations serve as important
reference points, against which we can measure, debate, and
innovate from.
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